Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development...
Tryp Therapeutics announces signing of definitive agreement with Exopharm Limited. The post Tryp Therapeutics To Be Acquired by Exopharm appeared first...
It is that time again when financial reports from the previous quarter start coming out. These documents let us know which companies are moving in a...
Tryp Therapeutics Inc. (“Tryp” or the “Company“) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin...
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled...
This year's Wonderland Conference in Miami provided inspiring and sometimes hilarious insights into the integration process of psychedelics entering mainstream...
The company is targeting a listing on the Australian Securities Exchange. The post Exopharm to Buy Tryp Therapeutics in All-Stock Deal appeared first on...
Filament Health has signed a non-binding term sheet for up to US$14.4 million in funding through a convertible note. The post Filament Health Announces...
Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses. The...
A bipartisan group of congressional lawmakers from both the House and the Senate have added funding for studies of psychedelic therapies into a major defense...